Education
About Us
Working with TipRanks
Follow Us
GlaxoSmithKline (GB:GSK)
LSE:GSK
GSK Stock Chart & Stats
1805.00p
-0.50p(-0.04%)
At close: 4:00 PM EST
1805.00p
-0.50p(-0.04%)
Day’s Range― - ―
52-Week Range1,242.50p - 1,830.00p
Previous CloseN/A
Volume367.08K
Average Volume (3M)8.54M
Market Cap
£71.92B
Enterprise Value73.93B
Total Cash (Recent Filing)£3.31B
Total Debt (Recent Filing)£17.75B
Price to Earnings (P/E)13.2
Beta0.85
Next Earnings
Feb 04, 2026EPS Estimate
0.24Last Dividend Ex-Date
Nov 13, 2025Dividend Yield3.31%
Share Statistics
EPS (TTM)0.55
Shares Outstanding4,060,484,900
10 Day Avg. Volume6,837,178
30 Day Avg. Volume8,542,213
Financial Highlights & Ratios
PEG Ratio-0.44
Price to Book (P/B)4.02
Price to Sales (P/S)1.75
P/FCF Ratio15.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£1,788.33Price Target Upside-0.92% Downside
Rating ConsensusHold
Number of Analyst Covering13
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe company's guidance for the full year 2025 has been raised, with expectations for higher sales, operating income, and earnings per share.
Market OpportunitiesPotential approval and market opportunity of Camlipixant for chronic cough and Bepirovirsen for HBV represent significant revenue opportunities with peak sales expectations.
Product LaunchesGSK's two key product launches, Blenrep in multiple myeloma and Depe in asthma, are expected to provide more upside than downside due to conservative consensus estimates.
Bears Say
Competition And Market LimitationsMixed physician feedback and building competition from JNJ's Tecvayli could limit the commercial opportunity for Blenrep.
Patent Cliff ConcernsConcerns exist around the decline in HIV sales due to the patent cliff, with a potential impact on margins being a primary worry for investors.
Restrictive RegulationsThe FDA has approved GSK’s Blenrep but the label is seen as restrictive, limiting potential growth.
GlaxoSmithKline News
GSK FAQ
What was GlaxoSmithKline’s price range in the past 12 months?
GlaxoSmithKline lowest share price was 1242.50p and its highest was 1830.00p in the past 12 months.
What is GlaxoSmithKline’s market cap?
GlaxoSmithKline’s market cap is £71.92B.
When is GlaxoSmithKline’s upcoming earnings report date?
GlaxoSmithKline’s upcoming earnings report date is Feb 04, 2026 which is in 58 days.
How were GlaxoSmithKline’s earnings last quarter?
GlaxoSmithKline released its earnings results on Oct 29, 2025. The company reported 0.55p earnings per share for the quarter, beating the consensus estimate of 0.47p by 0.08p.
Is GlaxoSmithKline overvalued?
According to Wall Street analysts GlaxoSmithKline’s price is currently Overvalued.
Does GlaxoSmithKline pay dividends?
GlaxoSmithKline pays a Quarterly dividend of 16p which represents an annual dividend yield of 3.31%. See more information on GlaxoSmithKline dividends here
What is GlaxoSmithKline’s EPS estimate?
GlaxoSmithKline’s EPS estimate is 0.24.
How many shares outstanding does GlaxoSmithKline have?
GlaxoSmithKline has 4,060,484,900 shares outstanding.
What happened to GlaxoSmithKline’s price movement after its last earnings report?
GlaxoSmithKline reported an EPS of 0.55p in its last earnings report, beating expectations of 0.47p. Following the earnings report the stock price went up 6.569%.
Which hedge fund is a major shareholder of GlaxoSmithKline?
Currently, no hedge funds are holding shares in GB:GSK
GlaxoSmithKline Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
£1,788.33 (-0.92% Downside)
£1,788.33 (-0.92% Downside)
Insider Transactions
Sold Shares
Worth £2.6M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.62%
12-Months-Change
Fundamentals
Return on Equity
36.44%
Trailing 12-Months
Asset Growth
2.05%
Trailing 12-Months
Company Description
GlaxoSmithKline
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
GSK Stock 12 Month Forecast
Average Price Target
1,788.33p
▼(-0.92% Downside)
Technical Analysis
AstraZeneca
―
ConvaTec
―
Hikma Pharmaceuticals
―
Smith & Nephew
―
Beximco Pharmaceuticals Limited Sponsored GDR RegS
―
Options Prices
Currently, No data available
---